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ABSTRAK
Lupus eritematosus sistemik (LES) adalah penyakit autoimun kronik eksaserbatif dengan manifestasi klinis 
yang beragam. Psoriasis vulgaris adalah penyakit kulit yang menyerang 1-3% dari populasi. Patofisiologi 
mengenai tumpang tindihnya penyakit tersebut belum sepenuhnya diketahui. Hal ini menyebabkan adanya 
tantangan tersendiri dalam tatalaksana kedua penyakit tersebut. Dua orang laki-laki dengan LES dan psoriasis 
vulgaris dilaporkan dengan manifestasi klinis eritroderma berulang dengan fotosensitif. Perbaikan klinis dicapai 
setelah terapi kombinasi metilprednisolon dengan metotrexat. Adanya LES yang tumpang tindih psoriasis 
vulgaris merupakan suatu fenomena klinis yang langka. Hubungan kedua penyakit tersebut dapat berupa saling 
mendahului atau tumpang tindih pada suatu waktu yang sama dan memiliki hubungan dengan adanya anti-
Ro/SSA. Adanya tumpang tindih dari dua penyakit tersebut memberikan paradigma baru dalam patofisiologi, 
diagnosis, dan tatalaksana di masa mendatang.
Kata kunci: lupus eritematosus sistemik, psoriasis vulgaris, psoriatic artritis, overlap syndrome.
ABSTRACT
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with various clinical disorders and 
frequent exacerbations. Psoriasis vulgaris is a common skin disorder which affect 1-3% of general populations. 
The pathophysiology regarding the coexistence of these diseases is not fully understood. Therapeutic challenges 
arise since the treatment one of these diseases may aggravate the other. We reported two cases of SLE with 
psoriasis vulgaris with clinical manifestations as recurrent erythroderma with photosensitivity. Improvement in 
clinical condition was observed after treating the patients with methylprednisolone combined with methotrexate. 
The coexistence SLE and psoriasis are considered very rare. The presence of this overlap syndrome may precede 
one another or occur simultaneously and is closely related with the presence of anti-Ro/SSA. Thus, it raises new 
challenge regarding its relationships, diagnosis, therapeutic, and management.
Keywords: systemic lupus erythematosus, psoriasis vulgaris, psoriatic arthritis, overlap syndrome.
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INTRODUCTION
Systemic Lupus Erythematosus (SLE) is 
a chronic exacerbative autoimmune disease 
with various clinical disorders. Cutaneous 
manifestations are frequent in SLE, as much 
as 70-80% patients develop skin lesions during 
the disease progression and approximately 20% 
of SLE patients have skin lesions as initial 
presentation. Cutaneous manifestations in SLE 
can be divided into acute, subacute, and chronic 
cutaneous lupus erythematosus (CCLE). The 
most common cutaneous manifestations are 
malar rash, photosensitivity, discoid lesions, and 
alopecia. Other manifestations such as Raynaud 
phenomenon, livido reticularis, panniculitis, 
bullous lesions, vasculitic purpura, and urticaria 
may be related but not specific to SLE.1,2
Subacute cutaneous lupus erythematosus 
(SCLE) distribution is more extensive than 
chronic cutaneous lupus erythematosus. SCLE 
also has the tendency to spare the face with 
minimal or no scarring. The most common types 
are papulosquamous and annular polycyclic 
lesion. Other SCLE presentations such as 
erythroderma, erythema multiforme, toxic 
epidermal necrolysis like lesion (Rowell 
syndrome), and generalized poikiloderma are 
uncommon and considered as rare type of 
SCLE.3,4 Majority of patients with SCLE are 
associated with anti-Ro antibodies but only 50% 
of patients meet criteria for SLE. Patients with 
SCLE usually have mild systemic symptoms 
with arthritis and myalgia are the most common 
symptom. Other more severe symptoms such as 
lupus vasculitis, CNS lupus, and nephritis are 
scarce and only occur in less than 10%.2
Psoriasis vulgaris is a skin disease which 
affects approximately 1-3% in general 
population.5 It is a chronic inflammatory skin 
disease. Inflammatory arthritis is a common 
clinical manifestation in psoriasis patient, 
approximately affecting 25% psoriasis pasien. It 
affects both men and women equally and at the 
age of 30-50 years old. Psoriatic arthritis (PsA) 
is a seronegative spondyloarthritis due to the 
potential of axial joint involvement and enthesitis 
as its pathogenesis. The presentation is variable 
and can range from mild to debilitating, erosive 
arthropaty.6
The coexistence of SLE and PsA is very rare 
with a prevalence of 0.6%.7 Psoriasis generally 
precedes the SLE. Phototherapy which is common 
management in patient with psoriasis may act 
as a trigger for SLE. Common problems are 
diagnostic problem and therapeutic management 
as SLE is a seropositive arthritis while PsA is a 
seronegative arthritis, and hydroxychloroquin as 
well as systemic corticosteroids may exacerbate 
psoriasis.8 Therefore, we reported a case series of 
patients with psoriatic-like skin lesion presenting 
as erythroderma.
CASE ILLUSTRATION
Case 1
A 45-year-old male came into the emergency 
department with persistent scaling and redness 
of the skin. History taking revealed persistent 
scaling and redness of the skin had occurred 
since 7 months before. Scaling of the skin was 
preceded by redness, and skin eruptions in 
extensor area of extremities. History of taking 
antibiotics, non-steroid anti-inflammatory drugs, 
and pain killer drugs was not reported. There 
were no constitutional symptoms like fever, 
fatigue, nausea, shortness of breath, vomiting, 
and weight loss. He was anxious about his 
medical condition and had insomnia since 2 
months before. Joint pain was felt on both hands, 
fingers, and knees. Previous medication history 
revealed the presence of psoriasis vulgaris based 
on skin biopsy which did not improve with 
methotrexate 15 mgs weekly, type 2 diabetes 
mellitus with insulin, and depression. He worked 
as an officer in a construction company and had 
a history of photosensitivity with sun exposure. 
Family histories of psoriasis and connective 
tissue diseases were negative. 
Physical examination revealed a fully alert 
with normal, vital signs, thorax, and abdominal 
examinations. Extremities examinations revealed 
the presence of joint swelling without tenderness 
in PIP and DIP I-II-III-IV-V, as well as bilateral 
knees. Erythroderma presenting as generalized 
maculae with squamae was evident in ≥10% 
of his Body Surface Area (BSA) (Figure 1). 
Psoriatic nail was evident in fingers and toes. 
Laboratorium parameter showed hemoglobin 
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13.5 g/dL, leukocytes 13.14 µ/L, neutrophils 
62.3%, platelets 345 µ/L, albumin 2.86 g/dL, 
fasting glucose level 200 mg/dL, 2-hours post 
prandial glucose level 315 mg/dL, and low level 
of potassium 3.0 mEq/L. Renal and liver function 
tests are within normal limit.
Immunology parameter revealed ANA test 
was positive 1:151.4, ANA profile showed the 
presence of anti Ro/SSA (Ro-52 recombinant), 
rheumatoid factor, and IgM anti MCV. Radiology 
examination revealed seagull appearance in PIP 
and DIP joints in both sides of hands (Figure 
2), degenerative disease of the spine without 
sacroilitis. Skin biopsy revealed the presence of 
elongated rete ridges, parakeratosis, acanthosis 
concurrent with psoriasis. His Dermatology Life 
Quality Index (DLQI) score was 24. Systemic 
lupus erythematosus (SLE) and psoriatic arthritis 
were diagnosed in this patient based on SLICC 
criteria which showed the presence of depression, 
skin lesion, skin rash (erythroderma), arthritis, 
along with the presence of ANA and anti Ro/SSA 
as the immunology criteria, SLE and psoriatic 
arthritis were assessed in this patient.
Pulse dose of 500 mg methylprednisolone 
was administered in 3 days, methotrexate 15 mg 
po/weekly along with folic acid supplementation 
and basal bolus insulin regimen. Intravenous 
methylprednisolone was tapered to 1 mg/kgBW 
after pulse dose. Scaling of the skin was improved 
there was no new episode of scaling, and joint 
pain was improved by the 6th day after pulse dose 
of methylprednisolone. He was discharged from 
hospital with methylprednisolone, methotrexate, 
basal bolus insulin, and education about his 
current condition.
Case 2
A 79-year-old male came into emergency 
department with scaling of the skin since 3 
days ago. He had a history of generalized 
erythematous lesion 3 weeks before admission. 
Scaling of the skin was preceded with redness 
and itch in all areas of his body. Constitutional 
symptoms like fever, dyspnea, and joint pain was 
reported. Joint pain in both knees, fingers, and 
toes were reported since 4 months ago. Morning 
stiffness were also felt for 40 minutes. History 
of photosensitivity, recurrent painless oral thrush 
since 6 months ago were reported. There was 
no history of weight loss, nausea, vomiting, nor 
diarrhea. Skin biopsy revealed the presence of 
psoriasis vulgaris. He is a retired clerk, with 9 
children spent his time mostly by gardening. 
There was no family history of autoimmune nor 
metabolic diseases.
Figure 1. Physical appearance of the patient. The right side 
showed the presence of psoriatic nail with erythematous 
maculae and squamae.
Figure 2. The presence of seagull-like appearance showed 
the evidence of psoriatic arthritis in both hands
Figure 3. The presence of generalized erythroderma in 
this patient
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Physical examination revealed the presence 
of edema in bilateral pretibial. Dermatological 
examination revealed the presence of Auspitz’s 
sign and erythroderma in ≥10% BSA (Figure 3). 
Laboratory parameter showed hemoglobin 11.5 
g/dL, leukocytes 8,500 µ/L, neutrophils 45%, 
eosinophils 11.9%, lymphocytes 51%, platelets 
42,000 µ/L, albumin 2.9 g/dL, CRP 80 mg/dL, 
AST 44 IU/L, and ALT 65 IU/L. His ANA-IF 
revealed the nucleoplasm speckled pattern 
≥1:1000, cytoplasmic homogenous 1:100, 
whereas anti Ro/SSA was negative.
Bilateral knee x-ray examinations revealed 
the presence of bilateral entesopathy (Figure 
4) and gull wing appearance in both PIP II-III-
IV-V. His DLQI score was 7. Based on his age, 
the presence of, skin rash, thrombocytopenia, 
arthritis, photosensitivity, and ANA-IF, SLE was 
assessed in this patient. Therefore, SLE + psoriatic 
polycyclic plaques. Other forms, such as 
erythroderma, erythema multiforme-like lesions, 
and generalized-poikiloderma may occur and 
regarded as a rare type of SCLE.3 The presence of 
SCLE is closely associated with the presence of 
anti-Ro/SSA.9 The key mechanism in SLE is the 
production of autoantibodies which are produced 
by polyclonal B cell activation or autoantigen 
directed immune stimulation. Several factors 
such as genetic, environmental, and hormonal 
factors are the trigger of SLE.10
The presence PsA is approximately 25% 
in patients with psoriasis. It is characterized 
by stiffness, pain, swelling, and tenderness of 
the joints as well as surrounding areas, such 
as ligaments and tendons. It affects both male 
and female equally and typically presents at 
the age of 30 to 50 years. The presence of 
cutaneous symptoms usually precedes the 
onset of PsA. It is considered as a seronegative 
spondyloarthritis. The clinical manifestasions 
ranges from mild arthritis to severe, debilitating, 
and erosive arthropathy.6,11 Imaging examinations 
such as conventional radiography, computed 
tomography, magneting resonance, skeletal 
scintigraphy, positron emission tomography, 
and fluoroscopic optical imaging are helpful in 
making diagnosis, evaluating, and monitoring 
disease progression. Conventional radiography 
may reveal the combination of destructive 
changes such as erosions, tuft resorption, and 
osteolysis with bone proliferation including 
periostitis, ankulosis, spur formation, as well 
as non-marginal syndesmophytes. Though 
less sensitive than the others, conventional 
radiography remains highly specific compared 
to CT in detection of joint erosions.12
The etiology and pathogenesis of psoriasis 
are not yet understood, but it is thought to be 
a multifactorial disease comprises of genetic 
disposition and environmentalrisk factors 
which act as trigger factors, such as stress, 
trauma, infections, and drugs. Psoriasis shares 
both immunologic and genetic risk factors with 
other autoimmune diseases such as rheumatoid 
arthritis (RA) and SLE. The role of novel CD4 T 
effector cells (TH17) plays an important role in 
autoimmune inflammatory response. The main 
cytokines secreted by TH17 is IL-6, IL-17, IL-
Figure 4. The presence of entesopathy bilateral.
arthritis was assessed in this patient. Supportive 
treatment was given due to recent pneumonia 
and older age. Intravenous methylprednisolone 
1 mg/kgBW was administered for 7 days and 
methotrexate 10 mg/weekly. Upon treatment, 
symptoms were gradually improved including no 
new rash, increased platelets (68,000 µ/L) and he 
was discharged after 10 days of hospitalization. 
DISCUSSION
Subacute cutaneous lupus erythematosus 
clinical manifestations occurred mostly in 
females. Its lesions present with erythematous 
macules and papules that evolve into scaly 
papulosquamous (psoriasiform) or annular/
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21, and IL-22. Keratinocytes hyperproliferation 
is induced by IL-21 and IL-22. Thus, the current 
postulate that in a genetically predisposed an 
unknown stimulus are needed on epidermal 
keratinocytes to produced tumor necrosis factor 
(TNF)-a, interferon (IFN)-a, and IFN-g. These 
mediators will activate dendritic cells and induce 
the differentiation of naïve T cells into TH1 and 
TH17 which would migrate to skin, acting as 
antigen presenting cells and releasing cytokines, 
such as TNF-a, IFN-g, IL-23, IL-22, and IL-
17. Those cytokines induced proliferation of 
keratinocytes and alter their maturation, resulting 
the epidermal hyperproliferation, together 
with inflammatory T cell infiltration are the 
fundamental basis psoriatic lesions.10
The presence of SLE and psoriasis itself is 
very rare. The association between these two 
disease is not yet fully understood even though 
there should be the trigger that induce the 
development of both diseases.13 It is known that 
T cells play a central role in the development 
of psoriasis whereas B cells do in SLE. This 
fact leads to the view that superantigens might 
be the common mediator, but it is known that 
alterations of TH17 may occur in both diseases. 
The presence of IL-17 and IL-23, cytokines 
which are produced by TH17 subset play a role 
to the renal damage in SLE patients.10 The onset 
of both diseases might precede one another or 
occur simultaneously in a person. Patients with 
overlap syndrome of SLE and psoriasis have an 
increased risk for photosensitivity which was 
evident in both cases.5,13
The presence of SLE and psoriasis raises 
question about how to diagnose both diseases. 
The coexistence of these diseases is associated 
to ANA and anti-Ro/SSA (52-recombinant). 
Cozzani et al.14, reported that ANA was present 
in 98% SLE patients and 57% psoriasis patients. 
Anti-Ro/SSA’s presence were reported in 
psoriasis and SLE. Silvy et al.15, reported that 
Anti-Ro/SSA was present in 3 out of 200 
psoriasis cases, whereas Johnson et al, reported 
its prevalence was 2% in biologically agent 
naïve psoriatic arthritis patients. Anti-Ro/SSA’s 
presence was also reported in SLE patients. 
Cozzani et al.14, reported its prevalence was 
80% in SCLE patients, another report by 
Lopez-longo et al.16, showed that anti-Ro/SSA 
was detected in 88% patients with SCLE.9,14-17 
Though antibodies to Ro/SSA was pivotal in 
the diagnosis of SLE and psoriasis, some cases 
reported with this overlap syndrome reported the 
absence of antibody to Ro/SSA antibody. Thus, 
detailed medical history taking, including the 
history of previous medication, photosensitivity, 
and other constitutional symptoms must be done 
meticulously.10
Histologic examination, serology, and 
immunofluorescence test (lupus band test) are 
useful to search for the deposit of immunoglobulin 
and complement components in dermoepidermal 
junction which is seen in SLE patients. The most 
frequent immunoglobulin class deposited is 
IgM, seen in 90% of lesional skin biopsies. It is 
helpful in diagnosing SCLE or Chronic Lupus 
Cutaneous from other type of SLE since it is only 
positive in skin lesion. The disadvantages are 
the presence of antibody is found in 60-100% 
biopsy samples and its wide range of sensitivity 
(10.5-78.9%) as well as specificity (47.8-97.8%) 
depending on the criteria used.18,19 We thought 
there was a strong indication to perform lupus 
band test to confirm SLE diagnosis in both 
cases, but we could not do that due to lack of 
equipment. Therefore, we diagnosed SCLE in 
case 1 based on refractory erythroderma which 
was unresponsive to psoriasis medication. 
Thrombocytopenia can be found in psoriasis 
patient after receiving anti-TNF therapy, and case 
2 was naïve to psoriasis medication.20 Therefore, 
based on his age, thrombocytopenia, arthritis, 
photosensitivity, and ANA test, we diagnosed 
this patient with SLE and psoriasis.
The coexistence of these diseases raises 
question about the management to control 
both diseases simultaneously. The control of 
SLE requires the administration of systemic 
corticosteroid, especially in SLE with renal or 
central nervous system involvement. Failure 
in corticosteroid tapering may induce rebound 
flare of psoriasis or psoriatic erythroderma. 
Phototherapy though favorable for psoriasis 
in most cases must be put into consideration 
as it can trigger SLE flare. Antimalarial agents 
which widely used in cutaneous and joints 
manifestations may aggravate or precipitate 
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psoriasis. Patients with cutaneous SLE who 
develops psoriasis after the administration of 
antimalarial agents should be evaluated for the 
possibility of drug-induced psoriasis.10,13
Biologic agents, like etanercept or infliximab 
may be used to control psoriasis but its adverse 
effect such as anti-TNFa induced lupus (ATIL) 
must be considered. Though reversible through 
withdrawal of therapy, the clinical manifestations 
may involve renal and central nervous system. 
Systemic corticosteroids or immunosuppressants 
often needed to control moderate-to-severe 
psoriasis. Moderate-to-severe psoriasis is 
defined as the presence of skin lesion >10% BSA 
and DLQI score >10. Glucocorticoid pulse is 
indicated in severe psoriasis.21,22 Methotrexate 
is the only agent that is known successfully 
treating the coexistence of these diseases. In our 
cases both patients were administered systemic 
corticosteroids.10
We administered pulse dose of 500 mg 
intravenous methylprednisolone in case 1 
because of the severe psoriasis which presented 
as recurrent generalized erythroderma in ≥10% 
of his BSA and DLQI score was 25. We did 
not administer pulse dose of corticosteroids to 
case 2 because he was an elderly patient and 
the history of recent infection. Therefore, we 
used intravenous methylprednisolone 1 mg/
kgBW with close monitoring to the platelet 
counts. Methotrexate was given to both cases. 
The clinical condition of case 1 improved 
dramatically after pulse dose of corticosteroids 
and methotrexate 15 mg/weekly. There was 
no new rash and he could resume his daily 
activities. Patient in case 2 had a worse prognosis 
because of his age and many comorbid factors, 
such as history of infection in previous hospital 
admission.
CONCLUSION
It has been reported a case series of coexistence 
of SLE and psoriasis with erythroderma as 
its manifestation. The coexistence of both 
diseases is rare and poses new challenge in 
discovering its relationships, therapeutical 
management, and education. The presence of 
this overlap syndrome may precede one another 
or occur simultaneously and is closely related 
with the presence of anti-Ro/SSA. Lupus 
Band test is helpful to search for immune 
complex deposition in skin lesion. Therapeutic 
challenges occur in which suppression of SLE 
activity with corticosteroids or antimalarial 
agents may aggravate or precipitate psoriasis 
and phototherapy or biologic agents may 
trigger SLE flare. Thus, proper history taking 
should be performed in order to diagnose this 
rare phenomenon and giving comprehensive 
managements are key to suppress the acitivities 
of both diseases.
COMPETING INTEREST
The authors declare that there is no conflict 
of competing interest regarding the publication 
of this article.
ACKNOWLEDGMENTS
We acknowledge Poernomo Boedi Setiawan, 
dr. Sp.PD-KGEH as the head of Internal 
Medicine Department of Airlangga University 
for giving us permission to manage and write 
this case report. We also acknowledge all staffs 
in our department for the support given to us. 
REFERENCES
1. Cojocaru M, Cojocaru IM, Silosi I, Doina C. 
Manifestations of systemic lupus erythematosus. J Clin 
Med. 2011;6(4):330-6.
2. Okon LG, Werth VP. Cutaneous lupus erythematosys: 
Diagnosis and treatment. Best Pract Res Clin 
Rheumatol. 2013;27(3):391-404.
3. Mutasim DF. Severe subacute cutaneous lupus 
erythematosus presenting with generalized 
erythroderma and bullae. J Am Acad Dermatol. 
2003;48(2):947-9.
4. Pai V, Naveen K, Athanikar S, Dinesh U, Reshme P, 
Divyashree R. Subacute cutaneous lupus erythematosus 
presenting as erythroderma. Indian J Dermatol. 
2014;59(6):634-8.
5. Avriel A, Zeller L, Flusser D, Abu Shakra M, Halevy 
S, Sukenik S. Coexistence of psoriatic arthritis and 
systemic lupus erythematosus. Israel Med Assoc J. 
2007;9(2):48-9.
6. Lloyd P, Ryan C, Menter A. Psoriatic arthritis: An 
Update. Arthritis. 2012:1-7.
7. Dubois E. Lupus-specific skin disease.  Dubois’ lupus 
erythematosus. 2nd Edition. In: Wallace DJ, Hahn BH, 
eds. Los Angeles: University of Southern California 
Press; 1974. p. 559-64.
8. Berthelot C, Nash J, Duvic M. Coexistent psoriasis 
150
Hendra Gunawan                                                                                                      Acta Med Indones-Indones J Intern Med
and lupus erythematosus treated with alefacept. Am J 
Clin Dermatol. 2007;8(1):47-50.
9. Kuhn A, Sontheimer R, Ruzicka T. Clinical 
manifestations of cutaneous lupus erythematosus. 
cutaneous lupus erythematosus. First edition. In: Kuhn 
A, Lehmann P, Ruzicka T, eds. Heidelberg: Springer-
Verlag Berlin. 2005.
10. Cuesta ML, I B. Connective tissue diseases and psoriasis. 
Actas Dermo-sifiliograficas. 2011;102(7):487-97.
11. Boehncke W, Qureshi A, Merola J, et al. Diagnosing 
and treating psoriatic arthritis: an update. British J 
Dermatol. 2014;170(1):772-86.
12. Aleo E, Migone S, Prono V, Barbieri F, Garlaschi 
G, Cimmino MA. Imaging techniques in psoriatic 
arthritis: Update 2012−2014 on current status and 
future prospects. J Rheumatol. 2015;93(1):53-6.
13. Pramatarov K, Tsankov N. Association of cutanous 
lupus erythematosus with other dermatological 
diseases. Cutaneous lupus erythematosus. First edition. 
In: Kuhn A, Lehmann P, Ruzicka T, eds. Heidelberg: 
Springer-Verlag Berlin; 2005.
14. Cozzani E, Drosera M, Gasparini G, Parodi A. 
Serology of lupus erythematosus: Correlation between 
Immunopathological features and clinical aspects. 
Autoimmune Diseases. 2014;1:1-13.
15. Silvy F, Bertin D, Bardin N, et al. Antinuclear 
antibodies in patients with psoriatic arthritis treated or 
not with biologics. PLoS ONE. 2015;10(7):e0134218.
16. Lopez-Longo F, Monteagudo I, Gonzalez C, Grau R, 
Carreno L. Systemic lupus erythematosus: clinical 
expression and anti-Ro/SS&mdash; A response in 
patients with and without lesions of subacute cutaneous 
lupus erythematosus. Lupus. 1997;6:32-9.
17. Johnson S, Schentag C, Gladman D. Autoantibodies in 
biological agent naive patients with psoriatic arthritis. 
Annals Rheum Dis. 2005;64:770-2.
18. Meurer M. Immunopathology of cutaneous lupus 
erythematosus. Cutaneous lupus erythematosus. First 
edition. In: Kuhn A, Lehmann P, Ruzicka T, eds. 
Heidelberg: Springer-Verlag Berlin; 2005.
19. Reich A, Marcinow K, Birula-Bialynicki R. The lupus 
band test in systemic lupus erythematosus patients. 
Ther Clin Risk Manag. 2011;7:27-32.
20. Balato N, Gallo L, Gaudiello F, Chiurazzi F, Ayala 
F. Transient and reversible thrombocytopenia 
in a psoriatic patient treated with etanercept. J 
Dermatological Treatment. 2010;21:117-8.
21. Mrowietz U, Kragballe K, Reich K, et al. Definition 
of treatment goals for moderate to severe psoriasis: a 
European consensus. Arch Dermatol Res. 2011;303:1-
10.
22. Sinha A, Bagga A. Pulse steroid therapy. Indian J Ped. 
2008;75(1):1057-66.
